CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
46.09
-1.17 (-2.48%)
Nov 21, 2024, 11:04 AM EST - Market open
CRISPR Therapeutics AG Revenue
CRISPR Therapeutics AG had revenue of $602.00K in the quarter ending September 30, 2024. This brings the company's revenue in the last twelve months to $202.83M, up 19.31% year-over-year. In the year 2023, CRISPR Therapeutics AG had annual revenue of $371.21M with 30,885.48% growth.
Revenue (ttm)
$202.83M
Revenue Growth
+19.31%
P/S Ratio
19.32
Revenue / Employee
$498,351
Employees
407
Market Cap
3.93B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 371.21M | 370.01M | 30,885.48% |
Dec 31, 2022 | 1.20M | -913.77M | -99.87% |
Dec 31, 2021 | 914.96M | 914.24M | 127,154.94% |
Dec 31, 2020 | 719.00K | -288.87M | -99.75% |
Dec 31, 2019 | 289.59M | 286.47M | 9,169.85% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Oscar Health | 8.22B |
Organon & Co. | 6.41B |
ICU Medical | 2.34B |
Haemonetics | 1.36B |
Sotera Health Company | 1.12B |
Prestige Consumer Healthcare | 1.11B |
Ultragenyx Pharmaceutical | 522.75M |
TG Therapeutics | 264.79M |
CRSP News
- 13 hours ago - CRISPR Therapeutics AG (CRSP) Jefferies London Healthcare Conference (Transcript) - Seeking Alpha
- 5 days ago - CRISPR Therapeutics AG (CRSP) Guggenheim Inaugural Healthcare Innovation Conference (Transcript) - Seeking Alpha
- 7 days ago - CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference - GlobeNewsWire
- 9 days ago - Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism - Seeking Alpha
- 16 days ago - CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 24 days ago - Crispr Therapeutics: Poised For A Major Turnaround - Seeking Alpha
- 6 weeks ago - Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma - Seeking Alpha
- 2 months ago - Crispr Therapeutics: Prepare To Be Bored - Seeking Alpha